No Data
No Data
Perspective Therapeutics Price Target Cut to $27.00/Share From $29.00 by RBC Capital
Perspective Therapeutics Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Cuts Target Price to $27
RBC Capital Reaffirms Their Buy Rating on Perspective Therapeutics (CATX)
RBC Adjusts Perspective Therapeutics' PT to $27 From $29, Keeps Outperform Rating, Speculative Risk
Express News | Perspective Therapeutics Inc : RBC Cuts Target Price to $27 From $29
No Data